Potential New Drug Targets IDed for Deadly Viruses

GEN | August 14, 2019

New research from investigators at Cornell University not only uncovered how two highly lethal viruses have greater pathogenic potential when their proteins are combined but may have also stumbled upon potential novel targets to combat these diseases. The Cornell team was studying how the Nipah and Hendra viruses attach to, and fuse with, their hosts’ cell within the fruit bat. Findings from the new study were published recently in the Journal of Virology “Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes.” “Co-infections with these two viruses can occur in the same host, but we didn’t know what would happen if their proteins combined,” noted senior study investigator Hector Aguilar-Carreno, PhD, associate professor in the department of microbiology and immunology at Cornell. “We discovered that not only could they work together, but they can also work even better than they do separately.” The researchers’ focus is on the viral fusion proteins (or F proteins) and attachment proteins (G proteins). In previous studies, the team unveiled how the two proteins physically interact to enable viral infections: A G protein attaches to the cell; G then triggers F to flip up and down, triggering fusion between the cellular and viral membranes—the first moment of infection.

Spotlight

BioTechnology Engineering is a part of Engineering where Biology Research & Development is Combined with technology to make the Human Life Better and Smarter.

Spotlight

BioTechnology Engineering is a part of Engineering where Biology Research & Development is Combined with technology to make the Human Life Better and Smarter.

Related News

Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases

Amagma Therapeutics | January 19, 2022

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The collaboration will allow Innovent to access novel, first-in-class molecules for inflammatory disorders with little to no existing treatment options. Amagma will secure clinical manufacturing for its lead programs and gain a proven regional partner with extensive expertise in protein engineering and manufacturing. Under the terms of the agreement, Innovent will be responsible for the manufacture of the three programs through a Phase 2 study and, if Innovent exercises its option, research, development, and commercialization of each program in Greater China. Amagma will continue to be responsible for global research and development prior to option exercise and ex-China research, development and commercialization thereafter. Amagma is eligible to receive development, approval, and commercial milestones if Innovent exercises the options. Amagma may also receive royalties on net sales of any commercial products in the territory. “This transaction highlights an innovative approach to securing manufacturing expertise in exchange for insights into novel disease biology from our SEIZMIC™ platform. Innovent has demonstrated themselves to be an excellent partner with robust capabilities and strong execution. We look forward to working with Innovent to potentially advance these novel therapies.” Tillman Gerngross, Ph.D., Co-founder, Chairman, Amagma Therapeutics About Amagma Therapeutics Amagma Therapeutics is developing precision antibody therapeutics against inflammatory diseases which have proven to be intractable by other approaches. A number of these serious illnesses are driven by overactive extracellular proteases which can compromise organ function and fuel inflammation. The Company’s SEIZMIC proprietary discovery platform enables screening and development of highly selective antibodies that can inhibit dysfunctional enzyme activity. Amagma was founded in 2019 by serial entrepreneur scientists Leonard Zon and Tillman Gerngross. Amagma is based in Waltham, MA.

Read More

CELL AND GENE THERAPY

Boston Labs and Germfree Launch Mobile Cell and Gene Therapy (CGT) Manufacturing Platform

BOSTON LABS | September 23, 2021

Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. announced their partnership to launch a new network of mobile CGT manufacturing facilities. The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver CGT point-of-care contract manufacturing services. The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network of global point-of-care mobile contract manufacturing centers. Boston Labs is embedded within the Boston/Cambridge life science community which is home to more than 1000 biotech companies. 18 of the top 20 biopharmas have a major presence in the area, including Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio. As the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued. Our pivotal partnership with Germfree Laboratories, Inc. enables Boston Labs to readily deploy mobile manufacturing platforms to any clinical site globally where CGT trials are enrolling, eliminating logistical risks associated with transporting patient material under a critical timeline. This is the Future of Point-of-Care Cell and Gene Therapy Delivery. - Jon Mason, CEO of Boston Labs This groundbreaking collaboration with Boston Labs should deliver much needed process space and opportunities to showcase how next-generation cleanrooms and manufacturing facilities can accelerate the processes needed for the future. - Kevin Kyle, CEO of Germfree This partnership, designed to reduce client CGT manufacturing costs and complexities, delivers secure access to mobile GMP-compliant manufacturing facilities wherever they are needed. About Boston Labs: Founded in 2003, Boston Labs is a leading clinical logistics company, working with clients to streamline the complexities of biotech and pharmaceutical logistics and manufacturing. About Germfree: Germfree Laboratories Inc. creates environments that serve life science innovation and advance global health. They design and manufacture flexible cGMP-compliant cleanroom buildings and high containment facilities which are process or containment ready upon deployment.

Read More

CELL AND GENE THERAPY

PacBio Acquires Omniome, a DNA Sequencing Startup, for up to $800 Million

PacBio | July 26, 2021

Pacific Biosciences has had no trouble growing its business on its own in the year and a half since its acquisition by Illumina was blocked by the Federal Trade Commission due to concerns that the combination would establish a monopoly in DNA sequencing. Earlier this year, the sequencer manufacturer received a staggering $900 million investment from SoftBank—a commitment almost as large as the $1.2 billion promised by Illumina for the planned acquisition. PacBio is now making its acquisition, setting out a deal for up to $800 million to acquire Omniome, another provider of DNA sequencing technology. The majority of the transaction is comprised of planned upfront payments totaling about $600 million. This will be paid out in $300 million in cash and 9.4 million shares of PacBio common stock. The additional $200 million will come from milestone payments made when Omniome meets certain specified objectives, which will also be paid in a mix of cash and shares. PacBio has committed a small number of its current investors to a private issue of common stock to fund the acquisition. The total gross proceeds from this deal are expected to be about $300 million. Casdin Capital, SoftBank subsidiary SB Northstar LP, and T. Rowe Price Associates are among the investors who will buy approximately 11.2 million shares of PacBio stock for $26.75 per share, which is slightly less than the stock's closing price on the last full day of trading before the buyout was announced. PacBio will be able to extend the capabilities of its single-molecule, real-time sequencing technology, or SMRT Sequencing, for use by its clients in biomedical and infectious disease research, as well as therapeutic and diagnostic development, after the transaction is completed. PacBio's technology is based on long-read sequencing, which analyzes long strands of DNA at a time and can detect larger genomic variants and structural changes than short-read methods—though long-read sequencing has a higher potential error rate in those readings. Meanwhile, Omniome has created its short-read technology that concentrates on the proteins that bind to DNA to generate what it claims are more accurate analyses than existing short-read sequencers. Combining the two technologies is reminiscent of Illumina's planned acquisition of PacBio, which would have merged the latter's long-read technology with Illumina's short-read sequencing. The merger is a significant boost for Omniome, which has attracted several life sciences, investors since its inception in 2013. Each of its most two funding rounds—a series B in mid-2018 and a series C in early 2020—raised $60 million, bringing the San Diego-based startup's total funding to over $130 million.

Read More